ESTRO meets Asia 2024 - Abstract Book

S170

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

therapy with palliative doses and regimens were excluded from the study. Patients recruited were divided into two cohorts: radical CCRT (Arm A) and Induction Chemotherapy (IC) followed by Chemo Radiotherapy (CCRT) (Arm B) were evaluated. The patients were analyzed for overall survival (OS) and progression free survival (PFS).

Results:

One hundred and eighty (180) patients of locally advanced unresectable OSCC were treated with curative intent. However, data of 22 (12%) patients were excluded because of incomplete data in the database. Of remaining 158 patients, 120 (76%) and 38 (24%) were divided into arm A and B, respectively. Baseline characteristics were statistically similar in both arms except for sub site distribution with higher percentage of buccal mucosa primary [25.8% vs 42.1% in arm A vs. B respectively, p-value 0.047 ]. With a median follow-up of 16 (range 2 -73) months, the Progression Free Survival (PFS)observed was 11 vs. 12 months [p-value 0.460] and Overall Survival (OS) was 16 vs. 17 months [p-value 0.450] in arms A and B respectively.

Conclusion:

Our study showed IC doesn’t have benefit in terms of PFS or OS compared to upfront CCRT in unresectable OSCC treated in a definitive setting. However, a more robust data and literature is required to come up with a clear answer for this clinical question.

Keywords: oral, unresectable, chemoradiation,chemotherapy

References:

1) Madera M, Tirado Amador L, Leal Acosta C. Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review. Cancer Manag Res. 2021 Aug 25;13:6705-6719. doi: 10.2147/CMAR.S283204. PMID: 34471384; PMCID: PMC8403568. 2) Patil VM, Prabhash K, Noronha V, Joshi A, Muddu V, Dhumal S, Arya S, Juvekar S, Chaturvedi P, Chaukar D, Pai P, Kane S, Patil A, Agarwal JP, Ghosh-Lashkar S, Dcruz A. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol. 2014 Oct;50(10):1000-4. doi: 10.1016/j.oraloncology.2014.07.015. Epub 2014 Aug 15. PMID: 25130412. 3) Chaukar D, Prabash K, Rane P, Patil VM, Thiagarajan S, Ghosh-Laskar S, Sharma S, Pai PS, Chaturvedi P, Pantvaidya G, Deshmukh A, Nair D, Nair S, Vaish R, Noronha V, Patil A, Arya S, D'Cruz A. Prospective Phase II Open Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer. J Clin Oncol. 2022 Jan 20;40(3):272-281. doi: 10.1200/JCO.21.00179. Epub 2021 Dec 6. PMID: 34871101. 4) Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, Locati L, Scaramellini G, Fallai C, Licitra L. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 2014 Feb;25(2):462-6. doi: 10.1093/annonc/mdt555. Epub 2014 Jan 8. PMID: 24401930.

196

Digital Poster